scholarly journals Role of Fibroscan and Non Invasive Markers to Assess Hepatic Fibrosis and Steatosis at Initial Presentation of Patients with Hepatitis B

2020 ◽  
Vol 3 (8) ◽  
pp. 16-23
Author(s):  
Ankur Shah ◽  
Rathi Chetan ◽  
Shah Jayshri A
Keyword(s):  
Hepatitis B ◽  
Hepatic Fibrosis ◽  
Initial Presentation ◽  
Non Invasive

scholarly journals Role of liver biopsy versus non-invasive biomarkers for diagnosis of significant fibrosis and cirrhosis: a web-based survey

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Mohamed Alboraie ◽  
Marwa Khairy ◽  
Aisha Elsharkawy ◽  
Noha Asem ◽  
Mohamed El Kassas ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Liver Biopsy ◽  
Hepatic Fibrosis ◽  
Serum Biomarkers ◽  
Response To Treatment ◽  
Web Based ◽  
Non Invasive ◽  
Single Method ◽  
Radiological Methods

Abstract Background Liver biopsy is the standard reference for staging hepatic fibrosis. Non-invasive methods for assessment of hepatic fibrosis and cirrhosis are becoming increasingly popular. Objective We aimed at exploring the change in practice regarding the use of liver biopsy and non-invasive methods for staging hepatic fibrosis and cirrhosis among hepatologists. Methods We performed a survey-based study that recruited hepatologists from various Egyptian institutions. Physicians were deemed eligible if they had a degree in internal medicine with hepatology as a subspecialty. We utilized an online-based survey that assessed the acceptability and reliability of liver biopsy, serum biomarkers, and radiological tools for evaluating liver fibrosis and cirrhosis. Results A total of 573 responses were retrieved (response rate = 80.3%). Out of them, 58% were having more than 15 years of experience as a hepatologist. Liver biopsy is still considered the gold standard for assessment of hepatic fibrosis and cirrhosis by 61% of participants. Liver biopsy was accepted by 44% of their patients. 84% reported the need for a more practical alternative to liver biopsy to assess disease progression or response to treatment. 78.34% of participants know serum biomarkers, 84.08% reported that they were acceptable by their patients, 37.79% thought they are reliable. 95.4% were familiar with radiological methods of non-invasive assessment of hepatic fibrosis, 89.1% reported that radiological methods were acceptable by their patients, 62% think that they are reliable and 78% reported they were applicable in clinical practice. Sixty-five percent think that combining non-invasive methods is better than using a single method. Forty percent of participants thought that radiological methods are easier to use for assessment of hepatic fibrosis followed by a combination of non-invasive methods, serum biomarkers, and liver biopsy respectively. Conclusion In conclusion, liver biopsy is still considered the most reliable method for evaluation and staging of liver cirrhosis by hepatologists in Egyptian institutions, despite the modest acceptance by the patients. Nonetheless, non-invasive methods are gaining acceptance by Egyptian physicians and patients, and most of them consider these methods as reliable and applicable tools for predicting the course of liver cirrhosis.

Non-invasive markers of hepatic fibrosis in chronic Hepatitis B: A review

2007 ◽  
Vol 4 (1) ◽  
pp. 61
Author(s):  
Mamun Al-Mahtab ◽  
Salimur Rahman ◽  
Mobin Khan
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Hepatic Fibrosis ◽  
Non Invasive

Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up

2013 ◽  
Vol 58 (2) ◽  
pp. 408-414 ◽  
Author(s):  
Ruxandra Calin ◽  
Marguerite Guiguet ◽  
Nathalie Desire ◽  
Françoise Imbert-Bismut ◽  
Mona Munteanu ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Hepatic Fibrosis ◽  
Mixed Infection ◽  
Hiv Positive ◽  
B Virus

scholarly journals Identifying Possible Hepatic Fibrosis of Hepatitis B Origin Using Non-invasive Markers: A Case-control Study in the South West Region of Cameroon

2019 ◽  
pp. 1-12
Author(s):  
Kukwah Anthony Tufon ◽  
Henry Dilonga Meriki ◽  
Kwenti Emmanuel Tebit ◽  
Teuwafeu Denis Georges ◽  
Nyeke James Tony ◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Hepatitis B ◽  
Hepatic Fibrosis ◽  
Case Control Study ◽  
Case Control ◽  
Non Invasive ◽  
West Region ◽  
South West ◽  
Control Study ◽  
South West Region

Aim: HBV infection is known to cause liver fibrosis as well as some extrahepatic manifestations. We aimed at assessing hematological changes and identifying possible hepatic fibrosis of Hepatitis B origin using non-invasive markers (NIMs). Study Design: A hospital-based Case-control study Place and Duration of Study: Conducted at the Buea Regional Hospital, South West Region of Cameroon from February 2016 to December 2017 Methods: We enrolled HBV infected treatment naïve patients and “healthy” controls. All participants were subjected to alanine aminotransferase (ALT) and aspartate aminotransferase (AST) measurement, Full blood count (FBC), HBsAg, anti-HBc, HIV and HCV tests. Aspartate-platelet ratio index (APRI), fibrosis based on 4 factors (FIB-4), age-platelet index (API) and AST/ALT ratio (AAR) were generated from the test results. A questionnaire was administered to collect demographic data, alcohol consumption and history of liver/kidney disease or metabolic syndrome. Results: A total of 202 cases and 202 controls were enrolled. Hematocrit (HCT) was significantly higher (p<0.001) in cases than controls. The controls had significantly higher mean values for platelet (p=0.005), neutrophil (p=0.032) and number of individuals with AST/ALT ratio (AAR) ≥1. Liver fibrosis was significantly associated with cases than controls based on APRI (OR:6.06, CI:3.59-10.24), FIB-4 (OR:5.35, CI:2.75-10.39) and API (OR:8.02, CI:1.81-35.55). Among the HBV infected cases, 69 (34.2%), 36(17.8%) and 8(4.0%) had results indicative of fibrosis from at least 2, at least 3 and all 4 NIMs respectively. AAR detected possible fibrosis in 136 HBV infected cases of which up to 77 (56.6%) were not detected as fibrosis by the other NIMs. Conclusion: HBV infection affects neutrophil percentage, HCT, PLT, APRI, FIB-4 and API in our study population. AAR did not prove to be a reliable NIM. Using at least 3 NIMs for HBV infected patients can significantly scale up their reliability for determining liver fibrosis in clinical practice.

Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients

2016 ◽  
Vol 64 (4) ◽  
pp. 773-780 ◽  
Author(s):  
W. Ray Kim ◽  
Thomas Berg ◽  
Tarik Asselah ◽  
Robert Flisiak ◽  
Scott Fung ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Hepatic Fibrosis ◽  
Scoring Systems ◽  
Non Invasive

scholarly journals Investigating the Efficiency of APRI, FIB-4, AAR and AARPRI as Noninvasive Markers for Predicting Hepatic Fibrosis in Chronic Hepatitis B Patients in Bangladesh

2019 ◽  
Vol 13 (1) ◽  
pp. 34-40
Author(s):  
Fazley R. Sha ◽  
Moyen Uddin Pk ◽  
Nermeen Z. Abuelezz ◽  
Rumana Pervin ◽  
Rabiul I. Talukder ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Fibrosis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Hepatic Fibrosis ◽  
Receiver Operating Curve ◽  
Aspartate Transaminase ◽  
Training Cohort ◽  
Non Invasive ◽  
Cohort Groups

Background and Aims:Accurate, affordable non-invasive markers are highly needed for efficient diagnosis and management of liver fibrosis caused by chronic hepatitis B. This is the first study to investigate the diagnostic efficiency of Aspartate Transaminase to Platelet Ratio (APRI), Fibrosis Index (FIB-4), Aspartate transaminase to Alanine Transaminase Ratio (AAR) and AAR/Platelet ratio index (AARPRI) as non-invasive markers to predict hepatic fibrosis caused by Chronic Hepatitis B (CHB) in Bangladesh.Methods:In this study, a training cohort of 1041 CHB patients were recruited, whereas 104 and 109 CHB patients of matched ages were recruited as internal and external validation cohort groups respectively. Histological and hematological data were analyzed. METAVIR scoring system was used to classify liver fibrosis stages. Area Under Receiver Operating Curve (AUROC), correlations and cutoff values for the four diagnostic markers were calculated and assessed.Results:92%, 81% and 84% of the patients had liver fibrosis in the training cohort, internal and external cohort groups respectively. Among the four noninvasive panels, APRI showed the best area under ROC; (0.767, CI: 0.780-0.914; 0.775) for the training cohort, (0.775, CI: 0.693-0.857), and (0.847, CI: 0.780-0.914) for the internal and external cohorts respectively. Cut-off value of APRI was 0.512 with sensitivity/specificity of 84%/67% in training cohort, 81% / 66% in the internal cohort, and 88% / 66% in an external cohort. The odds ratio for APRI was 32.95 (95%CI: 4.746-228.862,p<0.001).Conclusion:Among all the four tested markers, APRI is the most accurate non-invasive test to predict major liver fibrosis (F2-3) in Bangladeshi CHB patients.

scholarly journals Role of the Aspartate Transaminase and Platelet Ratio Index in Assessing Hepatic Fibrosis and Liver Inflammation in Adolescent Patients with HBeAg-Positive Chronic Hepatitis B

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Yu Zhijian ◽  
Li Hui ◽  
Yao Weiming ◽  
Lin Zhanzhou ◽  
Chen Zhong ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Liver Biopsy ◽  
Hepatic Fibrosis ◽  
Aspartate Transaminase ◽  
Liver Inflammation ◽  
Adolescent Patients ◽  
Positive Chronic Hepatitis ◽  
Widespread Availability

This study described an index of aspartate aminotransferase-to-platelet ratio index (APRI) to assess hepatic fibrosis with limited expense and widespread availability compared to the liver biopsy in adolescent patients with CHB.

Sign in / Sign up

Export Citation Format

Share Document